Prostate Cancer

Enzalutamide (XTANDI) added to androgen deprivation therapy significantly extended radiographic progression-free survival compared with ADT alone in a phase III study of men with metastatic hormone-sensitive prostate cancer.

A higher OncotypeDX Genomic Prostate Score is associated with an increased risk of adverse pathology in patients who undergo delayed radical prostatectomy after a period of active surveillance.

Active surveillance is only moderately able to reduce the harmful effects of prostate cancer overdiagnosis from PSA testing, according to an analysis of the long-term outcomes of men enrolled in the Prostate Cancer Research International Active Surveillance program.

According to the updated report from the Prostate Cancer Intervention versus Observation Trial (PIVOT), radical prostatectomy had no significant benefit over observation for reducing mortality among men with clinically localized disease.

Test your knowledge of the ASTRO/ASCO/AUA guideline for use of hypofractionated radiation therapy in localized prostate cancer.

"This study highlights the need for each practice to perform a self-audit of its AS protocol and take all necessary measures to ensure that patients are not lost during the monitoring period," writes Badar M. Mian, MD.

Also learn about a new stone device, an at-home testosterone enanthate injection, and more.

Christopher P. Filson, MD, MS, Adam Kibel, MD, and Stacy Loeb, MD, MS, highlight the year’s most important advances in the disease state.

The public health impact of increasing paternal age requires further investigation, and clinicians should discuss with their patients the potential impact older fathers may have on their children, according to researchers at Stanford University School of Medicine, Stanford, CA.

To help the modern urologist, we list and briefly review the best apps to get urologists at all levels of expertise through their day.

Markers of bone metabolism improved in men with metastatic castration-refractory prostate cancer who received radium-223 (Xofigo) in addition to enzalutamide (XTANDI) compared with enzalutamide alone.

Latin-American men are less likely than non-Latin-American Caucasian men to receive guideline-recommended definitive treatment for high-risk localized prostate cancer, according to a recent study.

"Utilization analysis of health care resources must be free of bias, methodologically sound, and relevant to current practice," writes Deepak A. Kapoor, MD.

Patients who receive a radiation oncology consultation after being diagnosed with localized prostate cancer are much more likely to receive active therapy than men managed only by a urologist, and the men seen by a radiation oncologist are particularly likely to be treated with radiation therapy, according to a Canadian population-based, retrospective cohort study.

Phase III data indicate benefit only for a subset of patients.

"The list of methods and biomarkers to help patients and physicians decide whether to perform biopsy is continuously evolving," writes Sigrid Carlsson, MD, PhD, MPH.

Results of a prospective, multicenter study validate the clinical performance of a PSA isoform assay (IsoPSA) for predicting high-grade prostate cancer, Eric A. Klein, MD, reported at the AUA annual meeting in San Francisco.

In men undergoing prostate biopsy, use of prophylactic antibiotics has been increasing appropriately over time, and fluoroquinolones still dominate, results of an insurance claims database analysis show.

A multi-institutional consortium study conducted to fill a gap in knowledge about long-term outcomes of stereotactic body radiation therapy (SBRT) for low- and intermediate-risk prostate cancer shows that both the long-term efficacy and safety of SBRT compare favorably with the profiles of other established radiotherapy modalities.

A single baseline PSA measurement taken during midlife strongly predicted the subsequent diagnosis of aggressive prostate cancer up to 12 years later among African-American men in the U.S.

"While there was no further reduction of prostate cancer risk after finasteride was discontinued, there was also no evidence that stopping finasteride resulted in more cases of prostate cancer," writes Badar M. Mian, MD.

Retrospective cohort study identifies wide variation in treatment rates, spending.

Both the efficacy and safety of abiraterone acetate (ZYTIGA) treatment for metastatic castrate-resistant prostate cancer (mCRPC) appear to differ depending on race, according to results of Abi Race, a prospective, multicenter trial presented at the American Society of Clinical Oncology annual meeting in Chicago.

Median overall survival for African-American men with advanced prostate cancer who are treated with docetaxel (Taxotere) is similar to that of Caucasian men, according to an analysis of pooled data from nine randomized phase III clinical trials.